CVE:HLS - HLS Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$29.50
  • Forecasted Upside:
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00
+0.30 (1.20%)
Get New HLS Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLS

Analyst Price Target is C$29.50
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for HLS Therapeutics in the last 3 months. The average price target is C$29.50, with a high forecast of C$33.00 and a low forecast of C$26.00. The average price target represents a ∞ upside from the last price of C$0.00.

This chart shows the closing price for HLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in HLS Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2021Raymond JamesSet Price TargetOutperformC$26.00
10/28/2021Raymond JamesSet Price TargetOutperformC$26.00
8/17/2021Raymond JamesUpgradeMarket Perform ➝ OutperformC$24.00 ➝ C$26.00
8/6/2021Raymond JamesDowngradeOutperform ➝ Market PerformC$28.00 ➝ C$24.00
5/10/2021Raymond JamesSet Price TargetOutperformC$28.00
5/4/2021Raymond JamesSet Price TargetOutperformC$28.00
3/30/2021Raymond JamesSet Price TargetOutperformC$28.00
3/22/2021Raymond JamesSet Price TargetOutperformC$27.00
3/19/2021Canaccord GenuityBoost Price TargetC$30.50 ➝ C$33.00
3/16/2021Raymond JamesSet Price TargetOutperformC$27.00
2/4/2021Raymond JamesSet Price TargetOutperformC$27.00
1/29/2021Raymond JamesSet Price TargetOutperformC$27.00
8/7/2020Canaccord GenuityBoost Price TargetC$28.50 ➝ C$29.00
5/8/2020Canaccord GenuityLower Price TargetC$30.00 ➝ C$28.50
3/20/2020Canaccord GenuityLower Price TargetC$30.50 ➝ C$30.00
1/7/2020Canaccord GenuityBoost Price TargetC$26.50 ➝ C$30.50
1/2/2020Clarus SecuritiesReiterated RatingSpeculative Buy ➝ Buy
11/21/2019Clarus SecuritiesReiterated RatingSpeculative Buy
11/19/2019Canaccord GenuitySet Price TargetBuyC$22.50
10/4/2019Bloom BurtonUpgradeHold ➝ Buy
8/9/2019Bloom BurtonDowngradeBuy ➝ Hold
3/22/2019Bloom BurtonReiterated RatingBuy
(Data available from 11/27/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
HLS Therapeutics logo
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company was incorporated in 2014 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

49,300 shs

Average Volume

97,793 shs

Market Capitalization

C$384.86 million

P/E Ratio

N/A

Dividend Yield

1.46%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of HLS Therapeutics?

The following Wall Street analysts have issued research reports on HLS Therapeutics in the last twelve months: Canaccord Genuity, and Raymond James.
View the latest analyst ratings for HLS.

What is the current price target for HLS Therapeutics?

2 Wall Street analysts have set twelve-month price targets for HLS Therapeutics in the last year. Their average twelve-month price target is C$29.50. Canaccord Genuity has the highest price target set, predicting HLS will reach C$33.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of C$26.00 for HLS Therapeutics in the next year.
View the latest price targets for HLS.

What is the current consensus analyst rating for HLS Therapeutics?

HLS Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HLS will outperform the market and that investors should add to their positions of HLS Therapeutics.
View the latest ratings for HLS.

What other companies compete with HLS Therapeutics?

How do I contact HLS Therapeutics' investor relations team?

The company's listed phone number is 647-495-9000. The official website for HLS Therapeutics is www.hlstherapeutics.com.